Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Celgene-CELG -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (206)	12/10/1998 8:32:00 PM
From: Miljenko Zuanic	Respond to of 804

Peter: <<Good news for both sides. >> Agree. Still, let me write few world for those who may continue to be skeptical and think that this was CELG weakness. After BMS departure from T deal, ENMD had very small chance to market drug. So their option (to capitalize and profit from T right) was to enter in litigation with CELG (right for STEP program) or collaborate with CELG. There should be no doubt that FDA will allowed another T manufacturer or another STEP program. ENMD chose well. IMO, CELG enter in this deal with stronger position (news didn't mentioned any T right fee?). Also, because it will be very easy to track down who and for what T was prescribed, ENMD will receive royalty only for indications for which they have right. Did anyone listen today's conference call? Phone # for playback?(TIA) Miljenko